Jingsong Wang, Harbour BioMed CEO

Fol­low­ing se­cre­tive Ab­Cellera pact, Mod­er­na picks up an­oth­er an­ti­body dis­cov­ery deal via Har­bour Bio­Med

As it moves to po­si­tion it­self be­yond pan­dem­ic star­dom, Mod­er­na is spi­der­ing out in­to a num­ber of biotech spheres — work­ing on an Ebo­la vac­cine, look­ing in­to the next it­er­a­tion of can­cer cell ther­a­pies and spend­ing on an an­ti­body dis­cov­ery part­ner­ship.

In its lat­est move, Mod­er­na is adding an­oth­er an­ti­body dis­cov­ery col­lab­o­ra­tion — this time with Har­bour Bio­Med through its new sub­sidiary Nona Bio­sciences, it an­nounced Fri­day. Har­bour sports a plat­form that specif­i­cal­ly de­vel­ops heavy chain-on­ly an­ti­bod­ies, which it says are half the size of tra­di­tion­al an­ti­bod­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.